Scholars Central

Research articlePublished 30 Nov 2020

In Silico Studies for Design and Development of Inhibitor against COVID-19

Authors: Akshata R. Pahelkar, Pritam V. Bagwe, Khushboo Maurya, Nikhil R. Pahelkar, Shreerang V. Joshi, Vikas N. Telvekar

Drug Designing: Open Access

Volume 10 · Issue 1 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Aim: The COVID-19 pandemic as declared by WHO, reported its first case in Wuhan, Hunei province, China. The infections have now been widespread and as of 30th March 2020, 6, 93,224 infection cases and 33,106 deaths have been reported worldwide. This is an international concern related to public health. Several research studies are being carried on around the world to amid the crises. Various treatment and prevention hypothesis regarding vaccine development, repurposing of drugs along with development of new chemical entities are under investigation. COVID-19 is a virus from the coronavirus family of viruses of beta genus. It has similarity with the SARS-CoV which was reported earlier. We plan to propose a scaffold for designing peptide derived specific inhibitor against COVID-19. Methods: Our strategy involves designing a peptide inhibitor that will interact with RBM of the SARS-CoV-2 and inhibit its entry inside the cell. Computer Aided drug design is one of the tools available which can help in achieving productivity in less time span. We utilised online peptide designing platform called rosetta, Autodock Vena a computer aided drug designing software (Licensed to Mr. Nikhil Pahelkar) and Schrodinger’s Drug Discovery Suite (Licensed to ICT, Mumbai). Result: We propose a peptide based on the sequence of human ACE2 which interacts strongly with RBM of the SARS-CoV-2. Interested readers can utilize the sequence for further modification of the peptide sequence to convert it into a peptidomimetic.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDrug Designing: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Akshata R. Pahelkar”
  • BylineArticles whose byline prints “Pritam V. Bagwe”
  • BylineArticles whose byline prints “Khushboo Maurya”
  • BylineArticles whose byline prints “Nikhil R. Pahelkar”
  • BylineArticles whose byline prints “Shreerang V. Joshi”
  • BylineArticles whose byline prints “Vikas N. Telvekar”